

# Ariane Herrick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9546939/publications.pdf>

Version: 2024-02-01

309  
papers

17,940  
citations

18436

62  
h-index

16605

123  
g-index

313  
all docs

313  
docs citations

313  
times ranked

12343  
citing authors

#	ARTICLE	IF	CITATIONS
1	Barriers and Facilitators to Physical Activity for People With Scleroderma: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1300-1310.	1.5	4
2	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	0.9	10
3	Polarisation-sensitive optical coherence tomography measurement of retardance in fibrosis, a non-invasive biomarker in patients with systemic sclerosis. <i>Scientific Reports</i> , 2022, 12, 2893.	1.6	9
4	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022, 8, 45.	0.5	3
5	Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. <i>Nature Reviews Rheumatology</i> , 2022, 18, 276-285.	3.5	18
6	P230 Feasibility study of mobile phone photography as a possible outcome measure of systemic sclerosis-related digital ulcers. <i>Rheumatology</i> , 2022, 61, .	0.9	0
7	P228 Mobile phone thermal imaging as an ambulatory assessment tool in Raynaud's phenomenon. <i>Rheumatology</i> , 2022, 61, .	0.9	0
8	Imaging digital arteries in systemic sclerosis by tomographic 3-dimensional ultrasound. <i>Rheumatology International</i> , 2021, 41, 1089-1096.	1.5	4
9	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. <i>Rheumatology</i> , 2021, 60, 1410-1418.	0.9	20
10	Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS). <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 146-153.	1.0	4
11	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021, 140, 110314.	1.2	9
12	Low body weight and involuntary weight loss are associated with Raynaud's phenomenon in both men and women. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 153-160.	0.6	4
13	Quantitative nailfold capillaroscopy update and possible next steps. <i>Rheumatology</i> , 2021, 60, 2054-2065.	0.9	16
14	Systemic sclerosis skin is a primed microenvironment for soft tissue calcification—a hypothesis. <i>Rheumatology</i> , 2021, 60, 2517-2527.	0.9	9
15	Circulating collagen neo-epitopes and their role in the prediction of fibrosis in patients with systemic sclerosis: a multicentre cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e175-e184.	2.2	13
16	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.5	24
17	Temperature response to cold challenge and mobile phone thermography as outcome measures for systemic sclerosis-related Raynaud's phenomenon. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 479-484.	0.6	5
18	Raynaud's phenomenon and digital ulcers: advances in evaluation and management. <i>Current Opinion in Rheumatology</i> , 2021, 33, 453-462.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Corrigendum to: Systemic sclerosis-related digital ulcers; a pilot study of cutaneous oxygenation and perfusion. <i>Rheumatology</i> , 2021, 60, 2490-2490.	0.9	0
20	Associations with digital pitting in patients with systemic sclerosis: results of a retrospective analysis. <i>Scandinavian Journal of Rheumatology</i> , 2021, , 1-2.	0.6	0
21	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021, 22, 856.	0.7	4
22	Systemic sclerosis: clinical features and management. <i>Medicine</i> , 2021, , .	0.2	0
23	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology</i> , The, 2021, 3, e844-e854.	2.2	9
24	Ultrasound findings in finger flexor tendons in systemic sclerosis: A cross-sectional pilot study. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 77-82.	1.0	7
25	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. <i>Autoimmunity Reviews</i> , 2020, 19, 102458.	2.5	231
26	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	0.9	14
27	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020, 72, 723-733.	1.5	25
28	Three-dimensional optoacoustic imaging of nailfold capillaries in systemic sclerosis and its potential for disease differentiation using deep learning. <i>Scientific Reports</i> , 2020, 10, 16444.	1.6	19
29	Comparison between low cost USB nailfold capillaroscopy and videocapillaroscopy: a pilot study. <i>Rheumatology</i> , 2020, 60, 3862-3867.	0.9	12
30	cRel expression regulates distinct transcriptional and functional profiles driving fibroblast matrix production in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 3939-3951.	0.9	5
31	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020, 139, 110262.	1.2	25
32	Frontiers in translational systemic sclerosis research: A focus on the unmet 'cutaneous' clinical needs (Viewpoint). <i>Experimental Dermatology</i> , 2020, 29, 1144-1153.	1.4	8
33	Systemic sclerosis-related digital ulcers; a pilot study of cutaneous oxygenation and perfusion. <i>Rheumatology</i> , 2020, 59, 3573-3575.	0.9	3
34	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 2156-2158.	0.9	11
35	Connective tissue diseases (excluding SLE). <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101487.	1.4	0
36	Impact and associates of digital pitting in patients with systemic sclerosis: a pilot study. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 239-243.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Raynaud's phenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101474.	1.4	43
38	A pilot study of cutaneous oxygenation and perfusion in systemic sclerosis-related digital calcinosis. <i>Rheumatology</i> , 2020, 59, 3109-3111.	0.9	8
39	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	1.2	21
40	State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders. <i>Microvascular Research</i> , 2020, 130, 104006.	1.1	9
41	New perspectives in the imaging of Raynaud's phenomenon. <i>European Journal of Rheumatology</i> , 2020, 7, 212-221.	1.3	21
42	A feasibility study of a novel low-level light therapy for digital ulcers in systemic sclerosis. <i>Journal of Dermatological Treatment</i> , 2019, 30, 251-257.	1.1	10
43	RNASEH2B Related Adult-Onset Interferonopathy. <i>Journal of Clinical Immunology</i> , 2019, 39, 620-622.	2.0	6
44	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	5.8	100
45	Fast track algorithm: How to differentiate a scleroderma pattern from a non-scleroderma pattern. <i>Autoimmunity Reviews</i> , 2019, 18, 102394.	2.5	79
46	Systemic sclerosis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2019, 80, 530-536.	0.2	75
47	Imaging calcinosis in patients with systemic sclerosis by radiography, computerised tomography and magnetic resonance imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 279-282.	1.6	23
48	Do thermographic parameters help to classify patients with early systemic sclerosis?. <i>Rheumatology</i> , 2019, 58, 1105-1106.	0.9	1
49	Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 89-101.	1.0	18
50	SAT0296...FAST TRACK ALGORITHM: HOW TO DIFFERENTIATE A SCLERODERMA PATTERN FROM A NON-SCLERODERMA PATTERN. , 2019, , .		3
51	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology, The</i> , 2019, 1, e237-e246.	2.2	18
52	Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 230-234.	0.6	5
53	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
54	A randomised controlled trial of wax baths as an additive therapy to hand exercises in patients with systemic sclerosis. <i>Physiotherapy</i> , 2019, 105, 370-377.	0.2	9

#	ARTICLE	IF	CITATIONS
55	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. <i>Rheumatology</i> , 2019, 58, 468-475.	0.9	22
56	Nailfold capillaroscopyâ€”how many fingers should be examined to detect abnormality?. <i>Rheumatology</i> , 2019, 58, 284-288.	0.9	19
57	Raynaudâ€™s Phenomenon and Ulcers. , 2019, , 45-62.		0
58	Results from an American pilot survey among Scleroderma Clinical Trials Consortium members on capillaroscopy use and how to best implement nailfold capillaroscopy training. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 151.	0.4	5
59	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography. <i>Arthritis and Rheumatology</i> , 2018, 70, 903-911.	2.9	65
60	Longitudinal nailfold capillaroscopy tracking of microangiopathic changes in systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 1554-1554.	0.9	1
61	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	1.5	54
62	Automated structure and flow measurement â€” a promising tool in nailfold capillaroscopy. <i>Microvascular Research</i> , 2018, 118, 173-177.	1.1	23
63	Raynaudâ€™s Phenomenon. , 2018, , 445-451.		0
64	The assessment of nailfold capillaries: comparison of dermoscopy and nailfold videocapillaroscopy. <i>Rheumatology</i> , 2018, 57, 1115-1116.	0.9	18
65	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patientâ€™Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	1.5	8
66	Molecular Basis for Dysregulated Activation of <scp>NKX</scp>2â€”5 in the Vascular Remodeling of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 920-931.	2.9	12
67	Systemic sclerosis: clinical features and management. <i>Medicine</i> , 2018, 46, 131-139.	0.2	3
68	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
69	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
70	Tracking digital ulcers in systemic sclerosis: a feasibility study assessing lesion area in patient-recorded smartphone photographs. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1382-1384.	0.5	12
71	Reliability of simple capillaroscopic definitions in describing capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2018, 57, 757-759.	0.9	60
72	The role of capillaroscopy and thermography in the assessment and management of Raynaud's phenomenon. <i>Autoimmunity Reviews</i> , 2018, 17, 465-472.	2.5	33

#	ARTICLE	IF	CITATIONS
73	157â€fAutomated analysis of nailfold images from handheld devices. <i>Rheumatology</i> , 2018, 57, .	0.9	0
74	Patient-reported outcome instruments for assessing Raynaudâ€™s phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.0	33
75	159â€fDermoscopy versus videocapillaroscopy in the assessment of nailfold capillaroscopy images in patients with systemic sclerosis and healthy controls. <i>Rheumatology</i> , 2018, 57, .	0.9	0
76	Reliability of digital ulcer definitions as proposed by the UK Scleroderma Study Group: A challenge for clinical trial design. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 170-174.	1.0	27
77	127â€fQuality of life in patients with connective tissue diseases: results from the Lupus Extended Autoimmune Phenotype (LEAP) study. <i>Rheumatology</i> , 2018, 57, .	0.9	1
78	Should all digital ulcers be included in future clinical trials of systemic sclerosis-related digital vasculopathy?. <i>Medical Hypotheses</i> , 2018, 116, 101-104.	0.8	20
79	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	0.9	53
80	Quantifying Digital Ulcers in Systemic Sclerosis: Reliability of Computerâ€™Assisted Planimetry in Measuring Lesion Size. <i>Arthritis Care and Research</i> , 2018, 70, 486-490.	1.5	10
81	Digital ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, 14-25.	0.9	155
82	Therapeutic implications from the pathogenesis of Raynaudâ€™s phenomenon. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 723-735.	1.3	8
83	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	1.9	3
84	Analysis of <i>ATP8B4</i> F436L Missense Variant in a Large Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1337-1338.	2.9	9
85	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
86	Intra-and inter-observer reliability of nailfold videocapillaroscopy â€” A possible outcome measure for systemic sclerosis-related microangiopathy. <i>Microvascular Research</i> , 2017, 112, 1-6.	1.1	31
87	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
88	Quantitative outcome measures for systemic sclerosis-related Microangiopathy â€” Reliability of image acquisition in Nailfold Capillaroscopy. <i>Microvascular Research</i> , 2017, 113, 56-59.	1.1	23
89	Reduced perfusion in systemic sclerosis digital ulcers (both fingertip and extensor) can be increased by topical application of glyceryl trinitrate. <i>Microvascular Research</i> , 2017, 111, 32-36.	1.1	33
90	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794

#	ARTICLE	IF	CITATIONS
91	Points to considerâ€”Raynaudâ€™s phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v45-v48.	0.9	23
92	An international SURvey on non-iNvaSive tecHniques to assess the mlcrocirculation in patients with RayNaudâ€™s phEnomenon (SUNSHINE survey). <i>Rheumatology International</i> , 2017, 37, 1879-1890.	1.5	33
93	Quartz Crystal Microbalance Assay of Clinical Calcinosis Samples and Their Synthetic Models Differentiates the Efficacy of Chelation-Based Treatments. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 27544-27552.	4.0	5
94	Evidence-based management of Raynaudâ€™s phenomenon. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 317-329.	1.2	21
95	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2370-2379.	2.9	49
96	An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1453-1457.	1.0	25
97	A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 77-78.	0.6	3
98	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.0	25
99	Controversies on the Use of Steroids in Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 84-91.	1.0	13
100	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.0	62
101	ESVM guidelines â€” the diagnosis and management of Raynaudâ€™s phenomenon. <i>Vasa - European Journal of Vascular Medicine</i> , 2017, 46, 413-423.	0.6	78
102	Critical Ischemia in Patients with Raynaudâ€™s Phenomenon. , 2017, , 257-266.		0
103	Raynaudâ€™s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy. , 2017, , 297-316.		1
104	A pilot study using high-frequency ultrasound to measure digital ulcers: a possible outcome measure in systemic sclerosis clinical trials?. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 218-219.	0.4	9
105	Non-invasive Imaging of Localised Scleroderma for Assessment of Skin Blood Flow and Structure. <i>Acta Dermato-Venereologica</i> , 2016, 96, 641-644.	0.6	18
106	Systemic sclerosis-related calcinosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 194-203.	1.0	24
107	Microvascular Response in Patients with Complex Regional Pain Syndrome as Measured by Laser Doppler Imaging. <i>Microcirculation</i> , 2016, 23, 379-383.	1.0	5
108	Calcinosis preferentially affects the thumb compared to other fingers in patients with systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 317-320.	0.6	22

#	ARTICLE	IF	CITATIONS
109	Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers. <i>Current Opinion in Rheumatology</i> , 2016, 28, 577-585.	2.0	26
110	Raynaud's phenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 112-132.	1.4	78
111	Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 209-216.	1.6	25
112	Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?. <i>Arthritis Care and Research</i> , 2016, 68, 1340-1345.	1.5	15
113	Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 2527-2539.	2.9	122
114	Thermographic Abnormalities are Associated with Future Digital Ulcers and Death in Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 1519-1522.	1.0	19
115	Calcium channel blockers for primary Raynaud's phenomenon. <i>The Cochrane Library</i> , 2016, 2016, CD002069.	1.5	35
116	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 344-349.	1.6	66
117	BSR and BHPR guideline for the treatment of systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 1906-1910.	0.9	147
118	Brief Report: <i>IRF4</i> Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies. <i>Arthritis and Rheumatology</i> , 2016, 68, 2338-2344.	2.9	46
119	Influence of <i>TYK2</i> in systemic sclerosis susceptibility: a new locus in the IL-12 pathway. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1521-1526.	0.5	41
120	An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. <i>Rheumatology</i> , 2016, 55, 883-890.	0.9	121
121	History of surgical debridement, antientromere antibody, and disease duration are associated with calcinosis in patients with systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 114-117.	0.6	16
122	Improved Diagnosis of Systemic Sclerosis Using Nailfold Capillary Flow. <i>Lecture Notes in Computer Science</i> , 2016, , 344-352.	1.0	3
123	Pilot study assessing pathophysiology and healing of digital ulcers in patients with systemic sclerosis using laser Doppler imaging and thermography. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 100-105.	0.4	9
124	286.â€¢Pilot Study of Multispectral Imaging to Measure Skin Oxygenation in Healthy Controls and Patients with Systemic Sclerosis and Primary Raynaudâ€™s Phenomenon. <i>Rheumatology</i> , 2015, , .	0.9	1
125	Long-term outcome of patients with systemic sclerosis requiring home parenteral nutrition. <i>Clinical Nutrition</i> , 2015, 34, 991-996.	2.3	17
126	Sparing effect of hemiplegia on skin fibrosis and microvascular involvement: Reports of two cases of systemic sclerosis and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 597-601.	1.6	4



#	ARTICLE	IF	CITATIONS
127	Validation of a Novel Radiographic Scoring System for Calcinosis Affecting the Hands of Patients With Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2015, 67, 425-430.	1.5	44
128	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139
129	Abnormalities of selenium but not of copper homeostasis may drive tissue fibrosis in patients with systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 747-748.	0.9	5
130	Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 2015-2024.	0.9	108
131	Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing <i>GDF6</i> and <i>SDC2</i> and provides insight into systemic sclerosis pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1249-1256.	0.5	22
132	Management of Raynaud's Phenomenon and Digital Ulcers. Current Treatment Options in <i>Rheumatology</i> , 2015, 1, 68-81.	0.6	4
133	Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception. <i>Rheumatology</i> , 2015, 54, 1443-1447.	0.9	42
134	A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis—spectrum disorders. <i>Rheumatology</i> , 2015, 54, 1435-1442.	0.9	60
135	Whole finger iontophoresis of sodium nitroprusside to increase blood flow in patients with systemic sclerosis: Influence of concentration. <i>International Journal of Pharmaceutics</i> , 2015, 490, 446-449.	2.6	5
136	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2011-2019.	2.9	90
137	Evidence for a clinical association between body mass index and malabsorption in patients with systemic sclerosis. <i>Scandinavian Journal of Rheumatology</i> , 2015, 44, 341-342.	0.6	2
138	Primary Raynaud's Phenomenon. , 2015, , 81-93.		0
139	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.4	4
140	Further confirmation that digital ulcers are associated with the severity of abnormality on nailfold capillaroscopy in patients with systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 376-377.	0.9	19
141	HLA-DRB1 associations with rheumatoid arthritis-related pulmonary fibrosis. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 75-76.	0.6	6
142	A double-blind, randomized, placebo-controlled crossover trial of the $\beta_2$ -adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 948-952.	0.9	29
143	An Automated System for Detecting and Measuring Nailfold Capillaries. <i>Lecture Notes in Computer Science</i> , 2014, 17, 658-665.	1.0	18
144	Profound hypomagnesaemia causing symptomatic hypocalcaemia—an underdiagnosed and potentially life-threatening problem in systemic sclerosis?. <i>Rheumatology</i> , 2014, 53, 767-769.	0.9	4

#	ARTICLE	IF	CITATIONS
145	Treatment options in Raynaud's phenomenon. Expert Opinion on Orphan Drugs, 2014, 2, 271-282.	0.5	0
146	Pilot study to visualise and measure skin tissue oxygenation, erythema, total haemoglobin and melanin content using index maps in healthy controls. , 2014, , .		1
147	Identification of <i>IL12RB1</i> as a Novel Systemic Sclerosis Susceptibility Locus. Arthritis and Rheumatology, 2014, 66, 3521-3523.	2.9	29
148	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research and Therapy, 2014, 16, R6.	1.6	37
149	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. Clinical Rheumatology, 2014, 33, 207-214.	1.0	48
150	A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology, 2014, 53, 1422-1430.	0.9	25
151	A longitudinal study of ankle brachial pressure indices in a cohort of patients with systemic sclerosis. Rheumatology, 2014, 53, 2009-2013.	0.9	5
152	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. American Journal of Human Genetics, 2014, 94, 47-61.	2.6	182
153	Raynaud's phenomenon (secondary). Clinical Evidence, 2014, 2014, .	0.2	5
154	Nailfold Capillaroscopy in Pediatrics. Arthritis Care and Research, 2013, 65, 1393-1400.	1.5	38
155	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
156	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
157	Management of Raynaud's Phenomenon and Digital Ischemia. Current Rheumatology Reports, 2013, 15, 303.	2.1	41
158	A prospective study of systemic sclerosis-related digital ulcers: prevalence, location, and functional impact. Scandinavian Journal of Rheumatology, 2013, 42, 483-486.	0.6	47
159	Dr. Murray, et al reply. Journal of Rheumatology, 2013, 40, 206.2-206.	1.0	1
160	Cervical Spine Calcinosis in Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 1617-1618.	1.0	13
161	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.5	52
162	Confirmation of <i>TNIP1</i> but not <i>RHOB</i> and <i>PSORS1C1</i> as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.5	56

#	ARTICLE	IF	CITATIONS
163	Implication of <i>IL-2/IL-21</i> region in systemic sclerosis genetic susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1233-1238.	0.5	30
164	Simulating nailfold capillaroscopy sequences to evaluate algorithms for blood flow estimation. , 2013, 2013, 2636-9.		3
165	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. <i>PLoS ONE</i> , 2013, 8, e54419.	1.1	38
166	The influence of measurement location on reliability of quantitative nailfold videocapillaroscopy in patients with SSc. <i>Rheumatology</i> , 2012, 51, 1323-1330.	0.9	31
167	Malnutrition in systemic sclerosis. <i>Rheumatology</i> , 2012, 51, 1747-1756.	0.9	59
168	Acro-osteolysis in systemic sclerosis is associated with digital ischaemia and severe calcinosis. <i>Rheumatology</i> , 2012, 51, 2234-2238.	0.9	79
169	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. <i>Human Molecular Genetics</i> , 2012, 21, 926-933.	1.4	74
170	Comment on: A multicentre study on the reliability of qualitative and quantitative nailfold videocapillaroscopy assessment: reply. <i>Rheumatology</i> , 2012, 51, 1922-1922.	0.9	2
171	Percutaneous endoscopic gastrostomy feeding--a life-saving intervention in SSc-myositis overlap with pharyngeal dysfunction. <i>Rheumatology</i> , 2012, 51, 1518-1520.	0.9	5
172	Childrens' and parents' beliefs about childhood onset scleroderma are influenced by child age and physical function impairment. <i>Rheumatology</i> , 2012, 51, 1331-1333.	0.9	4
173	Noninvasive Measurement of Skin Autofluorescence Is Increased in Patients with Systemic Sclerosis: An Indicator of Increased Advanced Glycation Endproducts?. <i>Journal of Rheumatology</i> , 2012, 39, 1654-1658.	1.0	17
174	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. <i>Human Molecular Genetics</i> , 2012, 21, 2825-2835.	1.4	98
175	A multicentre study on the reliability of qualitative and quantitative nail-fold videocapillaroscopy assessment. <i>Rheumatology</i> , 2012, 51, 749-755.	0.9	65
176	System sclerosis. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2012, 73, 509-516.	0.2	5
177	Influence of the <i>IL6</i> Gene in Susceptibility to Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 2294-2302.	1.0	34
178	Infected Calcinosis of the Knee in Limited Cutaneous Systemic Sclerosis: Figure 1.. <i>Journal of Rheumatology</i> , 2012, 39, 2043-2044.	1.0	8
179	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. <i>Journal of Rheumatology</i> , 2012, 39, 112-118.	1.0	8
180	The pathogenesis, diagnosis and treatment of Raynaud phenomenon. <i>Nature Reviews Rheumatology</i> , 2012, 8, 469-479.	3.5	228

#	ARTICLE	IF	CITATIONS
181	Churgâ€“Strauss, a rare cause of intracerebral haemorrhage. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1177-1178.	0.8	5
182	Raynaudâ€™s Phenomenon. , 2012, , 313-329.		3
183	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. <i>Arthritis Research and Therapy</i> , 2012, 14, R273.	1.6	10
184	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R85.	1.6	32
185	Pilot study of intense pulsed light for the treatment of systemic sclerosis-related telangiectases. <i>British Journal of Dermatology</i> , 2012, 167, 563-569.	1.4	19
186	Pressure and pain In Systemic sclerosis/Scleroderma - an evaluation of a simple intervention (PISCES): randomised controlled trial protocol. <i>BMC Musculoskeletal Disorders</i> , 2012, 13, 11.	0.8	11
187	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
188	A rare polymorphism in the gene for Tollâ€“like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. <i>Arthritis and Rheumatism</i> , 2012, 64, 264-271.	6.7	77
189	Influence of Childhood Scleroderma on Physical Function and Quality of Life. <i>Journal of Rheumatology</i> , 2011, 38, 167-173.	1.0	35
190	The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis. <i>Journal of Inflammation Research</i> , 2011, 4, 61.	1.6	31
191	Contemporary management of Raynaud's phenomenon and digital ischaemic complications. <i>Current Opinion in Rheumatology</i> , 2011, 23, 555-561.	2.0	55
192	Preliminary Clinical Evaluation of Semi-automated Nailfold Capillaroscopy in the Assessment of Patients with Raynaudâ€™s Phenomenon. <i>Microcirculation</i> , 2011, 18, 440-447.	1.0	19
193	Clinical Images: Systemic sclerosis-related telangiectases. <i>Arthritis and Rheumatism</i> , 2011, 63, 572-572.	6.7	1
194	Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 775-782.	6.7	86
195	A replication study confirms the association of <i>TNFSF4 (OX40L)</i> polymorphisms with systemic sclerosis in a large European cohort. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 638-641.	0.5	63
196	Effects of Iloprost on Microvascular Structure Assessed by Nailfold Videocapillaroscopy: A Pilot Study: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 2079-2080.	1.0	16
197	Clinical features of childhood localized scleroderma in an incidence cohort. <i>Rheumatology</i> , 2011, 50, 1865-1868.	0.9	26
198	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2050-2052.	0.5	15

#	ARTICLE	IF	CITATIONS
199	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	1.5	201
200	A 22-Year-Old Woman with Raynaud's Phenomenon but No Other Symptoms and No Abnormalities on Examination. , 2011, , 23-29.		0
201	Epidemiology of systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 857-869.	1.4	90
202	Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. <i>Arthritis Care and Research</i> , 2010, 62, 213-218.	1.5	147
203	Clinical Images: Pachydermoperiostosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1538-1538.	6.7	0
204	Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 2595-2604.	6.7	85
205	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	9.4	351
206	Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 116-124.	1.0	51
207	Raynaud's Phenomenon and Hand Function in Patients with Rheumatoid Arthritis: Figure 1.. <i>Journal of Rheumatology</i> , 2010, 37, 1358.2-1359.	1.0	4
208	Thumb Involvement in Raynaud's Phenomenon as an Indicator of Underlying Connective Tissue Disease. <i>Journal of Rheumatology</i> , 2010, 37, 783-786.	1.0	51
209	Quantitative nailfold video capillaroscopy in patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2010, 49, 1699-1705.	0.9	37
210	Reliability of dermoscopy in the assessment of patients with Raynaud's phenomenon. <i>Rheumatology</i> , 2010, 49, 542-547.	0.9	38
211	Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. <i>Rheumatology</i> , 2010, 49, 1607-1608.	0.9	3
212	Nail-fold capillary abnormalities are associated with anti-centromere antibody and severity of digital ischaemia. <i>Rheumatology</i> , 2010, 49, 1776-1782.	0.9	35
213	Testing for Hypoxia in Forearm Skin of Patients with Systemic Sclerosis, Assessed by Pimonidazole. <i>Journal of Rheumatology</i> , 2010, 37, 1968.2-1969.	1.0	2
214	Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. <i>Rheumatology</i> , 2010, 49, 990-996.	0.9	24
215	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). <i>Journal of Rheumatology</i> , 2010, 37, 1673-1679.	1.0	9
216	Raynaud's Phenomenon. , 2010, , 387-393.		0

#	ARTICLE	IF	CITATIONS
217	Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis. <i>Rheumatology</i> , 2009, 48, 876-882.	0.9	36
218	A local approach to Raynaud phenomenon. <i>Nature Reviews Rheumatology</i> , 2009, 5, 246-247.	3.5	9
219	Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 878-882.	6.7	50
220	Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. <i>Arthritis and Rheumatism</i> , 2009, 61, 1103-1111.	6.7	106
221	Pilot study of dual-wavelength (532 and 633nm) laser Doppler imaging and infrared thermography of morphea. <i>British Journal of Dermatology</i> , 2009, 160, 864-867.	1.4	26
222	An investigation into the blood-flow characteristics of telangiectatic skin lesions in systemic sclerosis using dual-wavelength laser Doppler imaging. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 618-620.	0.6	2
223	Ocular Manifestations of Scleroderma. <i>Survey of Ophthalmology</i> , 2009, 54, 292-304.	1.7	82
224	Raynaud's phenomenon. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 146-155.	0.4	3
225	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
226	Diagnosis and Management of Scleroderma Peripheral Vascular Disease. <i>Rheumatic Disease Clinics of North America</i> , 2008, 34, 89-114.	0.8	63
227	Vasodilator iontophoresis a possible new therapy for digital ischaemia in systemic sclerosis?. <i>Rheumatology</i> , 2008, 47, 76-79.	0.9	24
228	Comment on: Sparing of the thumb in Raynaud's phenomenon: reply. <i>Rheumatology</i> , 2008, 47, 1260-1260.	0.9	2
229	Raynaud's phenomenon (secondary). <i>Clinical Evidence</i> , 2008, 2008, .	0.2	5
230	The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. <i>Rheumatology</i> , 2007, 46, 533-538.	0.9	87
231	Home parenteral nutrition--an effective and safe long-term therapy for systemic sclerosis-related intestinal failure. <i>Rheumatology</i> , 2007, 47, 176-179.	0.9	41
232	Sparing of the thumb in Raynaud's phenomenon. <i>Rheumatology</i> , 2007, 47, 219-221.	0.9	35
233	Heterozygous Mutations in TREX1 Cause Familial Chilblain Lupus and Dominant Aicardi-Goutières Syndrome. <i>American Journal of Human Genetics</i> , 2007, 80, 811-815.	2.6	339
234	Recombinant human anti-transforming growth factor $\beta$ 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415

#	ARTICLE	IF	CITATIONS
235	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007, 34, 501-9.	1.0	45
236	The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. <i>Human Pathology</i> , 2006, 37, 190-197.	1.1	93
237	Abnormal microvascular response is localized to the digits in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2006, 54, 1952-1960.	6.7	37
238	A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. <i>Arthritis and Rheumatism</i> , 2006, 54, 3962-3970.	6.7	632
239	Assessment of digital vascular structure and function in response to bosentan in patients with systemic sclerosis-related Raynaud's phenomenon. <i>Rheumatology</i> , 2006, 46, 363-364.	0.9	32
240	Expression of osteonectin and matrix Gla protein in scleroderma patients with and without calcinosis. <i>Rheumatology</i> , 2006, 45, 1349-1355.	0.9	49
241	Raynaud's Phenomenon. , 2006, , 313-319.		0
242	Acute intermittent porphyria. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 235-249.	1.0	66
243	Dual wavelength (532 and 633 nm) laser Doppler imaging of plaque psoriasis. <i>British Journal of Dermatology</i> , 2005, 152, 1182-1186.	1.4	18
244	Pathogenesis of Raynaud's phenomenon. <i>Rheumatology</i> , 2005, 44, 587-596.	0.9	339
245	A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis. <i>British Journal of Rheumatology</i> , 2005, 44, 536-538.	2.5	15
246	Possible therapeutic use of vasodilator iontophoresis. <i>Microvascular Research</i> , 2005, 69, 89-94.	1.1	20
247	Computerized nailfold video capillaroscopy--a new tool for assessment of Raynaud's phenomenon. <i>Journal of Rheumatology</i> , 2005, 32, 841-8.	1.0	80
248	Digital iontophoresis of vasoactive substances as measured by laser Doppler imaging--a non-invasive technique by which to measure microvascular dysfunction in Raynaud's phenomenon. <i>Rheumatology</i> , 2004, 43, 986-991.	0.9	45
249	<i>Mycobacterium chelonae</i> finger infection associated with Raynaud's phenomenon. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1178-1179.	0.5	4
250	Laser Doppler imaging: a developing technique for application in the rheumatic diseases. <i>British Journal of Rheumatology</i> , 2004, 43, 1210-1218.	2.5	80
251	Vascular imaging. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004, 18, 957-979.	1.4	17
252	Coexistence of systemic sclerosis and multiple sclerosis. <i>Journal of Neurology</i> , 2004, 251, 1524-1525.	1.8	13

#	ARTICLE	IF	CITATIONS
253	Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. <i>Arthritis and Rheumatism</i> , 2004, 50, 3985-3993.	6.7	656
254	Comparison of red and green laser doppler imaging of blood flow. <i>Lasers in Surgery and Medicine</i> , 2004, 35, 191-200.	1.1	32
255	Treatment of Raynaud's phenomenon: New insights and developments. <i>Current Rheumatology Reports</i> , 2003, 5, 168-174.	2.1	33
256	Occurrence of Raynaud's phenomenon in children ages 12-15 years: Prevalence and association with other common symptoms. <i>Arthritis and Rheumatism</i> , 2003, 48, 3518-3521.	6.7	39
257	Keloidal scleroderma. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 171-173.	0.6	12
258	Comparison of thermography and laser Doppler imaging in the assessment of Raynaud's phenomenon. <i>Microvascular Research</i> , 2003, 66, 73-76.	1.1	68
259	Seventeen-point dermal ultrasound scoring system—a reliable measure of skin thickness in patients with systemic sclerosis. <i>British Journal of Rheumatology</i> , 2003, 42, 1559-1563.	2.5	135
260	Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. <i>Rheumatology</i> , 2002, 41, 324-328.	0.9	95
261	Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 1007-1011.	0.5	78
262	Genetic epidemiology: systemic sclerosis. <i>Arthritis Research</i> , 2002, 4, 165.	2.0	41
263	Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2002, 46, 3312-3316.	6.7	91
264	Development of agents for the treatment of systemic sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1255-1264.	1.9	3
265	Antibodies against oxidized low-density lipoproteins in systemic sclerosis. <i>British Journal of Rheumatology</i> , 2001, 40, 401-405.	2.5	32
266	Foot problems in patients with systemic sclerosis. <i>British Journal of Rheumatology</i> , 2001, 40, 410-413.	2.5	34
267	Ankle brachial pressure index in systemic sclerosis: influence of disease subtype and anticentromere antibody. <i>Rheumatology</i> , 2001, 40, 1102-1105.	0.9	28
268	The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2001, 19, 4-8.	0.4	83
269	Vascular function in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2000, 12, 527-533.	2.0	109
270	Mixed connective tissue disease presenting with pneumonitis and pneumatosis intestinalis. <i>Arthritis and Rheumatism</i> , 2000, 43, 704.	6.7	9



#	ARTICLE	IF	CITATIONS
271	Nailfold video capillaroscopy in psoriasis. <i>British Journal of Dermatology</i> , 2000, 142, 1171-1176.	1.4	72
272	Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. <i>Rheumatology</i> , 2000, 39, 506-512.	0.9	79
273	The influence of age on nailfold capillary dimensions in childhood. <i>Journal of Rheumatology</i> , 2000, 27, 797-800.	1.0	22
274	A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, 349-56.	0.4	48
275	Lack of interaction between methotrexate and penicillins. <i>British Journal of Rheumatology</i> , 1999, 38, 284-284.	2.5	7
276	Interferon- $\gamma$ does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 1999, 42, 299-305.	6.7	201
277	Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. , 1999, 189, 273-278.		96
278	Giant cell arteritis in a patient with limited cutaneous systemic sclerosis.. <i>Rheumatology</i> , 1999, 38, 479-480.	0.9	12
279	Laser Doppler Imaging—A New Technique for Quantifying Microcirculatory Flow in Patients with Primary Raynaud's Phenomenon and Systemic Sclerosis. <i>Microvascular Research</i> , 1999, 57, 284-291.	1.1	65
280	No significant effects of sodium aurothiomalate on haem metabolism and mixed function oxygenase activity in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 461-2.	0.4	0
281	TGF $\beta$ —a role in systemic sclerosis?. , 1998, 184, 4-6.		62
282	Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 70-78.	0.5	98
283	Manchester experience in establishing a part-time MSc course in rheumatology. <i>Rheumatology</i> , 1998, 37, 1020-1022.	0.9	3
284	Prolidase deficiency and systemic lupus erythematosus. <i>Archives of Disease in Childhood</i> , 1997, 76, 441-444.	1.0	70
285	Advances in palliative care for the patient with scleroderma. <i>Current Opinion in Rheumatology</i> , 1996, 8, 555-560.	2.0	4
286	Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 223-227.	1.1	8
287	Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 122-127.	0.5	108
288	Investigation of anal function in patients with systemic sclerosis.. <i>Annals of the Rheumatic Diseases</i> , 1996, 55, 370-374.	0.5	15

#	ARTICLE	IF	CITATIONS
289	INCREASED NAILFOLD CAPILLARY DIMENSIONS IN PRIMARY RAYNAUD'S PHENOMENON AND SYSTEMIC SCLEROSIS. <i>Rheumatology</i> , 1996, 35, 1127-1131.	0.9	57
290	Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 1996, 23, 650-3.	1.0	18
291	DNA repair deficiency in systemic lupus erythematosus: cause or consequence of disease and implications for management. <i>Lupus</i> , 1995, 4, 423-424.	0.8	10
292	NEUROLOGICAL INVOLVEMENT IN SYSTEMIC SCLEROSIS. <i>Rheumatology</i> , 1995, 34, 1007-1008.	0.9	16
293	Plasma TGF beta in systemic sclerosis: a cross-sectional study.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 763-767.	0.5	37
294	Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 323-326.	0.5	50
295	Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia.. <i>Annals of the Rheumatic Diseases</i> , 1994, 53, 540-542.	0.5	58
296	Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. <i>Journal of Rheumatology</i> , 1994, 21, 1477-83.	1.0	75
297	Cholelithiasis in patients with variegate porphyria. <i>Journal of Hepatology</i> , 1991, 12, 50-53.	1.8	9
298	PRIMARY RAYNAUD'S PHENOMENON IN EARLY CHILDHOOD. <i>Rheumatology</i> , 1991, 30, 223-225.	0.9	9
299	Elevation of blood lactate and pyruvate levels in acute intermittent porphyria – A reflection of haem deficiency?. <i>Clinica Chimica Acta</i> , 1990, 190, 157-162.	0.5	14
300	Elevation of hormone-binding globulins in acute intermittent porphyria. <i>Clinica Chimica Acta</i> , 1990, 187, 141-148.	0.5	9
301	LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. <i>The Quarterly Journal of Medicine</i> , 1990, 75, 355-63.	1.0	17
302	CONTROLLED TRIAL OF HAEM ARGINATE IN ACUTE HEPATIC PORPHYRIA. <i>Lancet, The</i> , 1989, 333, 1295-1297.	6.3	74
303	Comparison of enalapril and atenolol in mild to moderate hypertension. <i>American Journal of Medicine</i> , 1989, 86, 421-426.	0.6	55
304	Acute intermittent porphyria in two patients on anticonvulsant therapy and with normal erythrocyte porphobilinogen deaminase activity.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 491-497.	1.1	10
305	Idiopathic haemochromatosis in a young female with amenorrhoea. <i>Journal of the Royal Society of Medicine</i> , 1989, 82, 556-8.	1.1	1
306	Celiprolol and verapamil in the treatment of essential hypertension. <i>American Heart Journal</i> , 1988, 116, 1437-1438.	1.2	9

#	ARTICLE	IF	CITATIONS
307	Biochemical investigation of hepatoerythropoietic porphyria " homozygous porphyria cutanea tarda. Biochemical Society Transactions, 1988, 16, 829-830.	1.6	2
308	Vascular diagnostics for Raynaud's phenomenon. Journal of Vascular Diagnostics, 0, , 127.	0.2	13
309	The need to accurately measure energy intake and expenditure in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 0, , 239719832210957.	1.0	0